30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Seikagaku up 5.9% in 2Q19 on US Reimbursement -



Seikagaku grew in the mid-single digits on increased volumes of their Gel-One viscosupplement and favorable reimbursement decisions from U.S. insurers.

  • Domestic shipments of ARTZ decreased in volume, but were partially offset by delayed orders from previous quarters
  • International sales of the Gel-One viscosupplement increased due to marketing efforts and favorable reimbursement decisions from insurers
  • Sales of five-injection SUPARTZ FX declined as the U.S. market shifts toward single-injection treatments


Performance by Segment

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):

  1Q19 1Q18 $ Chg % Chg
Orthobiologics $69.1 $65.2 $3.8 5.9%


Source: Seikagaku

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.